Lawmakers want to add more Chinese biotechs to defense list
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! It’s Meghana. Today, we learn that Verve Therapeutics is pausing the testing of its PCSK9-focused gene editing treatment. The FDA approves the first digital therapeutic from a pharma company, and we have a new biotech scoreboard for you.
Read Original Article: Lawmakers want to add more Chinese biotechs to defense list »
